Standout Papers

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes 2020 2026 2022 2024962
  1. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes (2020)
    Christopher P. Cannon, Richard E. Pratley et al. New England Journal of Medicine
  2. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes (2020)
    Darren K. McGuire, Weichung Shih et al. JAMA Cardiology

Immediate Impact

5 from Science/Nature 62 standout
Sub-graph 1 of 20

Citing Papers

Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes
2025 Standout
Tirzepatide for Obesity Treatment and Diabetes Prevention
2024 Standout
1 intermediate paper

Works of Weichung Shih being referenced

Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes
2020 Standout

Author Peers

Author Last Decade Papers Cites
Weichung Shih 1009 1955 458 792 31 2.7k
James P. Mancuso 1106 2467 404 1363 42 3.1k
Susan Huyck 1286 2467 455 950 57 3.5k
Ira Gantz 741 1755 378 666 23 2.2k
Remo H.M. Furtado 1023 2371 379 977 30 3.0k
Cordula Zeller 822 1987 417 870 41 2.5k
Afshin Salsali 1504 2997 330 1432 51 3.5k
Erica L. Goodrich 1002 2360 454 1230 53 3.4k
Thomas Meinicke 1007 2442 133 956 35 2.7k
David R. Powell 991 1802 161 849 39 2.6k
M.J. Whiting 938 1669 256 1564 39 3.6k

All Works

Loading papers...

Rankless by CCL
2026